CELESTONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CELESTONE (CELESTONE).
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
| Metabolism | Primarily hepatic via CYP3A4, though betamethasone is less dependent on this enzyme compared to other corticosteroids. Metabolized to inactive glucuronide and sulfate conjugates. |
| Excretion | Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%. |
| Half-life | Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression. |
| Protein binding | ~64% bound to albumin; minor binding to corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd: 1.3-1.8 L/kg (total body water distribution). |
| Bioavailability | Oral: ~100% (well absorbed); IM: variable but nearly complete; Topical: minimal systemic absorption except on damaged skin (~1-10%). |
| Onset of Action | IV: rapid (within minutes); IM: 6-12 hours; Oral: 1-2 hours. |
| Duration of Action | Duration of adrenal suppression: 48-72 hours; clinical anti-inflammatory effects persist for 24-72 hours depending on dose and route. |
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
| Dosage form | SYRUP |
| Renal impairment | No dosage adjustment required for renal impairment. Monitor fluid and electrolyte balance in severe impairment. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% with caution. |
| Pediatric use | 0.02-0.3 mg/kg/day in divided doses every 6-12 hours; maximum 7.2 mg/day. |
| Geriatric use | Initiate at lowest effective dose (0.6 mg/day) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CELESTONE (CELESTONE).
| Breastfeeding | Betamethasone is excreted in breast milk in low concentrations. M/P ratio: 0.15-0.33. At maternal doses ≤ 1 mg/kg/day, amounts ingested by infant are unlikely to cause systemic effects. No specific adverse effects reported. Breastfeeding is generally considered safe, but infant should be monitored for signs of adrenal suppression if high maternal doses are used chronically. |
| Teratogenic Risk | Betamethasone (active ingredient of Celestone) is a corticosteroid. First trimester: Use only if potential benefit justifies risk; animal studies show increased risk of cleft palate, but human data is limited. Second trimester: Possible increased risk of preterm delivery and low birth weight with chronic use; monitor fetal growth. Third trimester: Preferred for accelerating fetal lung maturity in preterm labor (single course); repeated courses may be associated with reduced fetal growth and adrenal suppression. Risk of neonatal adrenal insufficiency if used near term. |
■ FDA Black Box Warning
None officially. However, corticosteroids like betamethasone should be used with caution in patients with systemic fungal infections, and live vaccines should not be administered to patients on immunosuppressive doses.
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to betamethasone or any excipient","Administration of live or live attenuated vaccines if on immunosuppressive doses","Intrathecal administration (for parenteral forms)"]
| Precautions | ["May cause hypothalamic-pituitary-adrenal (HPA) axis suppression","Increased risk of infections","Masking of infection signs","Adverse effects on growth in children","Osteoporosis with long-term use","Psychiatric disturbances","Cushing's syndrome with prolonged use","Ocular effects (e.g., cataracts, glaucoma)","Withdrawal syndrome upon abrupt discontinuation"] |
| Food/Dietary | Avoid grapefruit and grapefruit juice; may increase betamethasone levels. Limit sodium intake to prevent fluid retention. Monitor potassium-rich foods if hypokalemia develops. No significant food-drug interactions otherwise. |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure (risk of hypertension), blood glucose (hyperglycemia), signs of infection (immunosuppression), adrenal function (if chronic use). Fetal: Growth parameters (ultrasound for weight, amniotic fluid, and fetal well-being) if repeated courses; heart rate monitoring during tocolysis. Neonatal: Adrenal function if maternal dose was high or given near term; assess for hyperbilirubinemia, hypocalcemia, and infection susceptibility. |
| Fertility Effects | Betamethasone may dose-relatedly affect menstrual cycle and ovulation. Chronic use can suppress pituitary-adrenal axis, leading to secondary amenorrhea and infertility. Reversible upon dose reduction or discontinuation. No known impact on spermatogenesis. |
| Clinical Pearls | Betamethasone (Celestone) is a long-acting corticosteroid with minimal mineralocorticoid activity, making it preferred for fetal lung maturation in preterm labor due to placental metabolism to inactive forms. For acute asthma exacerbations, oral betamethasone 1-2 mg/kg stat can be used as an alternative to prednisone. Avoid intradermal injection due to risk of skin atrophy. Monitor for adrenal suppression with prolonged use. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly without consulting your doctor. · Report unusual weight gain, swelling, or increased thirst/urination (signs of hyperglycemia). · Avoid live vaccines while on this medication. · Do not use for more than a few days unless directed; long-term use can increase infection risk. · Inform all healthcare providers you are taking this steroid. |